Search

While rotational atherectomy (RA) has been used as neointimal debulking technique for in-stent restenosis (ISR) for many years, there are only few reports describing the use of orbital atherectomy (OA) for ISR. The aim of the study was to compare the safety and efficacy of RA and OA for treatment of

Optimal treatment for in-stent restenosis (ISR) remains a matter of debate. While rotational atherectomy and laser atherectomy have been used as neointimal debulking techniques for ISR, there has been few reports on orbital atherectomy (OA) for ISR. The aim of the study was to evaluate the

It has been postulated that obstructive sleep apnea (OSA) induces atherosclerosis through direct and indirect atherogenic mechanisms. However, OSA patients carry a higher burden of conventional cardiovascular (CV) risk factors. Therefore, whether OSA is uniquely associated with atherosclerosis or it

Objectives We evaluated the impact of the everolimus-eluting stent (EES) on the frequency of stent thrombosis (ST), target vessel revascularization (TVR), myocardial infarction (MI), and cardiac death in randomized controlled trials comparing the EES to non–everolimus-eluting drug-eluting stents (EE-DES). Background Whether or not the unique properties of the EES translate into reductions in ST remains unknown. Methods We searched MEDLINE, Scopus, the Cochrane Library, and Internet sources for articles comparing outcomes between EES and non–EE-DES without language or date restriction. Randomized controlled trials reporting the frequency of ST were included. Variables relating to patient and study characteristics and clinical endpoints were extracted. Results We identified 13 randomized trials (n = 17,101) with a weighted mean follow-up of 21.7 months. Compared with non–EE-DES, the EES significantly reduced ST (relative risk [RR]: 0.55; 95% confidence interval [CI]: 0.38 to 0.78; p = 0.001), TVR (RR: 0.77; 95% CI: 0.64 to 0.92; p = 0.004), and MI (RR: 0.78; 95% CI: 0.64 to 0.96; p = 0.02). There was no difference in cardiac mortality between the groups (RR: 0.92; 95% CI: 0.74 to 1.16; p = 0.38). The treatment effect was consistent by different follow-up times and duration of clopidogrel use. The treatment effects increased with higher baseline risks of the respective control groups with the strongest correlation observed for ST (R 2 = 0.89, p Conclusions Intracoronary implantation of the EES is associated with highly significant reductions in ST with concordant reductions in TVR and MI compared to non–EE-DES. Whether these effects apply to different patient subgroups and DES types merits further investigation.

Orbital atherectomy (OA) is a recently developed atherectomy device for severely calcified lesions. We studied 1149 consecutive patients with severely calcified lesions undergoing PCI between 1/2013 and 6/2016 requiring adjunctive atherectomy. We followed patients for procedural complications and 1

Background: Impella and Intra-aortic balloon pump (IABP) are both used to provide hemodynamic support in high risk percutaneous coronary intervention (hPCI). We aimed to compare Impella vs IABP use in a stable hPCI population Methods: From our single center prospective PCI database, we identified

Background: The aim of this study was to assess the plaque characteristics of obstructive lesions in diabetes mellitus (DM) patients presenting with stable coronary artery disease (CAD) at the time of percutaneous coronary intervention, using multimodality intravascular imaging registry. Methods: A

We evaluated the impact of the everolimus-eluting stent (EES) on the frequency of stent thrombosis (ST), target vessel revascularization (TVR), myocardial infarction (MI), and cardiac death in randomized controlled trials comparing the EES to non-everolimus-eluting drug-eluting stents (EE-DES).Whether or not the unique properties of the EES translate into reductions in ST remains unknown.We searched MEDLINE, Scopus, the Cochrane Library, and Internet sources for articles comparing outcomes between EES and non-EE-DES without language or date restriction. Randomized controlled trials reporting the frequency of ST were included. Variables relating to patient and study characteristics and clinical endpoints were extracted.We identified 13 randomized trials (n = 17,101) with a weighted mean follow-up of 21.7 months. Compared with non-EE-DES, the EES significantly reduced ST (relative risk [RR]: 0.55; 95% confidence interval [CI]: 0.38 to 0.78; p = 0.001), TVR (RR: 0.77; 95% CI: 0.64 to 0.92; p = 0.004), and MI (RR: 0.78; 95% CI: 0.64 to 0.96; p = 0.02). There was no difference in cardiac mortality between the groups (RR: 0.92; 95% CI: 0.74 to 1.16; p = 0.38). The treatment effect was consistent by different follow-up times and duration of clopidogrel use. The treatment effects increased with higher baseline risks of the respective control groups with the strongest correlation observed for ST (R(2) = 0.89, p0.001).Intracoronary implantation of the EES is associated with highly significant reductions in ST with concordant reductions in TVR and MI compared to non-EE-DES. Whether these effects apply to different patient subgroups and DES types merits further investigation.